OWC Pharmaceutical Research Advances Its Multiple Myeloma Study to Animals

With In-Vitro Testing Complete, Company Starts Protocol For Pre-Clinical Efficacy and Safety Testing On Mice

29 Mar, 2016, 08:00 ET from OWC Pharmaceutical Research Corp.

PETACH TIKVA, Israel, March 29, 2016 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it has completed in-vitro testing on its formulation for multiple myeloma and is preparing to begin pre-clinical safety and efficacy studies on mice.

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )

The Company's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.

"The preliminary results of the in-vitro studies of our cannabinoid formulation on multiple myeloma were very positive, so we have decided to advance the study on live animals, in this case mice. We hope that the efficacy and safety will give us the comfort we need to continue on to the human stage of testing." said Dr. Yehuda Baruch, OWC's Director of Research.  

Dr. Baruch continued, "Multiple myeloma is a cancer of plasma cells in the bone marrow, and accounts for 2% of all cancer deaths. Each successful round of testing on our cannabinoid-centric formulations brings us closer to changing the way we treat patients suffering from this deadly disease."

About OWC Pharmaceutical Research Corp.    

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).  For more information, visit: http://www.owcpharma.com/

Notice Regarding Forward-Looking Statements   

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659

In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909

SOURCE OWC Pharmaceutical Research Corp.